One of the most compelling advantages of using a CD30 lateral flow assay (LFA) over the traditional enzyme-linked immunosorbent assay (ELISA) or immunohistochemistry for detecting BIA-ALCL lies in its cost-efficiency. This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.